Skin Toxicity
12
1
2
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.3%
1 terminated out of 12 trials
83.3%
-3.2% vs benchmark
8%
1 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (12)
Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences
Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields
Skin Toxicity by Oncological Therapies
Crisaborole Ointment for Skin Toxicity Induced by Cetuximab
Novel Skin Care for Chemotherapy- Related Dermatologic Toxicities
Novel Skin Care for Immunotherapy- Related Dermatologic Toxicities
Panitumumab Skin Toxicity Prevention Trial
Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy (DERMIA)
Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer
Potency of Topical Corticosteroids in Combination Preparations
Serum 25-OH Vitamin D Modulation by Sunbed Use According to EU Guideline EN 60335-2-27
Skin Care for Cancer Patients: A Product Satisfaction Survey